Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Oct 01, 2022 5:29pm
RE:RE:RE:RE:Thinking out loud
Agreed - we shouldn't see any odd side-effects but we do have something different this time around. I am assuming we will have a very high load dose - so - curious if that could have any strange
...more
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Oct 01, 2022 1:50pm
RE:RE:RE:Thinking out loud
If not mistaken this molar study will be on healthy patients. Shouldn't see any issues SE wise in acute that's not a nocebo (opposite of placebo effect)
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Oct 01, 2022 8:39am
RE:RE:Thinking out loud
Timing for the commercial study update is likely tied to P2 start and first enrollment (study pushed out as well). Since we didn't get either by Friday - highly likely we get it next week
...more
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 30, 2022 6:32pm
....
before you apply lipstick to the pig, you must sever the arteries and let the pig bleed out. This is often done by those who are on the inside .. ....
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 30, 2022 1:22pm
ZZZZZzzzzzzzzzz maybe next month
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 30, 2022 11:49am
Hey mugsy
You are a slimy Goof
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 28, 2022 3:42pm
No buyers, no sellers
(37)
•••
TheMadMonk
X
View Profile
View Bullboard History
Comment by
TheMadMonk
on Sep 26, 2022 5:52pm
RE:Thinking out loud
AllinATE, Please note that while the P2 molar trial is scheduled to start this week on the 28th, Dan did mention that it could be delayed a couple days. The independent
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 26, 2022 4:31pm
RE:Thinking out loud
AllinATE - trials are supposed to start by 28th - not sure when they'd news release the first enrollment. Could release information on the study this week - OR - do they do a combo news release ?
...more
(14)
•••
AllinATE
X
View Profile
View Bullboard History
Post by
AllinATE
on Sep 26, 2022 3:52pm
Thinking out loud
Shouldn't trials be starting this week? I wonder when the commercial study will be relased? Also aren't they supposed to reveal IBD candidate in Q4?
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 25, 2022 11:28pm
...
https://youtu.be/SHhrZgojY1Q
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 22, 2022 8:25pm
RE:RE:Back in @62
Well done AllinATE ... that's a very nice price !
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 22, 2022 8:24pm
RE:Morningstar's Quantitative Equity Research Report for ATE
Yes - interesting. Thanks for the post. Surely ... chronic had more uncertainty associated with it as it led us down the path to acute - for good reasons. Also - acute likely leads us to
...more
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 22, 2022 3:10pm
At least some are buying back
it was a foolish and ignorant move on JohnBoy to sell in the .60s. it shows very little concern for shareholders
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 22, 2022 3:07pm
Extreme uncertainty is when insiders sell at LOW
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >